

District Pharmacies (All)
District Hospitals (All)
Referral Hospitals (All)
Central medical stores (All)
Pharmaceutical Wholesalers (All)
Importers (All)
Retail Pharmacies (All)
Health centers (All)

## Title: Call for Quarantine for batches of Amoxicillin 250 mg capsules (AMOXIMED)

The role of the Rwanda FDA is to protect the public health by disseminating information on quality and safety of products regulated under the LAW N° 003/2018 of 09/02/2018 to health professionals and to other concerned organs.

Referring to the spontaneous reports from different Health facilities and retail Pharmacies and pharmacy wholesale, the products were reported with the issue of self-opening of capsules and leakage of powder when removed from the Jar for dispensing. We regret to notify that the following batches were found with that quality issue.

DESCRIPTION	BATCH	Mfg. Date	Exp. Date	Manufacturer
Amoxycillin BP 250 mg capsules (AMOXIMED)/1000 capsules	767190216	02/2019	02/2022	CSPC ZHONGNUO PHARMACEUTICALS/CHINA
Amoxycillin BP 250 mg capsules (AMOXIMED)/1000 capsules	767190207	02/2022	02/2022	CSPC ZHONGNUO PHARMACEUTICALS/CHINA
Amoxycillin BP 250 mg capsules (AMOXIMED)/1000 capsules	767190208	02/2022	02/2022	CSPC ZHONGNUO PHARMACEUTICALS/CHINA



## Action to be taken

Rwanda Food and Drug Authority instructs all importers, central medical stores, Pharmacy wholesalers, District Pharmacies, retailers, Public and Private Health Facilities in possession of that batch, to stop distribution, dispensing and administration of the above incriminated batch and return them to their suppliers for quarantine until deep investigation is concluded.

Sincerely,

Dr. Charles KARANGWA
Ag. Director General of Rwanda EDA

CC:

• Hon. Minister of Health

Hon. Minister of state in Charge of Primary Health care